The company delivered approximately 30 percent quarterly revenue growth in Q4 2025, with growth driven by increasing demand for Amtagvi. After ongoing improvements in operations and gross margin, Iovance is well positioned for future profitability. The company achieved 50% gross margin and $303M cash fund Iovance to Q3 2027.
Cyborg Score Rationale
Iovance has achieved significant commercial traction with accelerating revenue growth (~30% quarterly), FDA approval for flagship product Amtagvi, FDA Fast Track designation for pipeline asset, and improving profitability metrics (50% gross margin). However, the company faces execution risks on expanding indications and competition in cell therapy.
Top Insights
Strong commercial momentum: FY2025 revenue of $264M achieved guidance with 30% Q4 growth
Margin expansion: Gross margin improved to 50% driven by operational efficiency and manufacturing scale
Pipeline advancement: FDA Fast Track designation granted for lifileucel in NSCLC; clinical data positive across multiple solid tumors
Cash position solid: $303M cash runway extends to Q3 2027, supporting path to profitability
Named Competitors
CAR-T Cell Therapies — Established cell therapy competitors with approved products and large markets
Replimune (RP2) — OncolyticsCompetitor in immunotherapy for solid tumors
Alternative TIL Therapies — Emerging competitors developing next-generation TIL cell therapies
Recent Developments
(February 2026) Strong Q4 2025 results: $264M annual revenue, 30% quarterly growth, FDA Fast Track for NSCLC indication
(February 2026) Gross margin improved to 50% with operational efficiency gains; $303M cash runway to Q3 2027
(November 2025) Q3 2025 showed 13% quarterly revenue growth and gross margin improvement to 43%
Open the full interactive Iovance Biotherapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.